Roeland Nusse Power - 07 Mar 2024 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
Andrew Nick as Attorney-in-Fact for Roeland Nusse pursuant to Power of Attorney previously filed
Issuer symbol
TECH
Transactions as of
07 Mar 2024
Net transactions value
-$800,627
Form type
4
Filing time
11 Mar 2024, 16:04:29 UTC
Previous filing
30 Oct 2023
Next filing
28 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Sale $800,627 -10,400 -19% $76.98 43,097 07 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TECH Stock Options (Right to Buy) 17,040 07 Mar 2024 Common Stock 17,040 $21.84 Direct
holding TECH Stock Options (Right to Buy) 15,940 07 Mar 2024 Common Stock 15,940 $25.30 Direct
holding TECH Stock Options (Right to Buy) 12,500 07 Mar 2024 Common Stock 12,500 $31.26 Direct
holding TECH Stock Options (Right to Buy) 7,592 07 Mar 2024 Common Stock 7,592 $44.96 Direct
holding TECH Stock Options (Right to Buy) 8,044 07 Mar 2024 Common Stock 8,044 $50.41 Direct
holding TECH Stock Options (Right to Buy) 6,028 07 Mar 2024 Common Stock 6,028 $63.92 Direct
holding TECH Stock Options (Right to Buy) 2,532 07 Mar 2024 Common Stock 2,532 $128.81 Direct
holding TECH Stock Options (Right to Buy) 3,460 07 Mar 2024 Common Stock 3,460 $73.94 Direct
holding TECH Stock Options (Right to Buy) 3,937 07 Mar 2024 Common Stock 3,937 $61.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.955 to $77.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.